Showing posts with label prostrate. Show all posts
Showing posts with label prostrate. Show all posts

Wednesday, November 2, 2011

Prostate Cancer Found in 2,000-Year-Old Mummy

A 2150-year-old Egyptian mummy has just revealed small, round lesions—the oldest case of metastatic prostate cancer in ancient Egyptians.

Prostate cancer,‭ ‬one of the most common types of modern malignancies,‭ ‬did affect the ancient Egyptians,‭ ‬according to a radiological investigation of a‭ 2,250‭ ‬year old-mummy.

Kept at the National Archaeology Museum of Lisbon,‭ ‬and catalogued as M1,‭ ‬the unnamed wrapped Ptolemaic mummy‭ (‬c.‭ ‬285‭–‬30‭ ‬BCE‭) ‬was adorned with a cartonnage mask and bib,‭ ‬and boasted an elaborately painted shroud.

The mummy is that of an adult male‭ "a view further justified by the preserved male perineal anatomy and an obvious mummified penis,‭" ‬Carlos Prates,‭ ‬a radiologist at Imagens Médicas Integradas in Lisbon,‭ ‬and colleagues write in a study now in press in the International Journal of Paleopathology.‭

The man,‭ ‬about‭ ‬5ft‭ ‬5in tall,‭ ‬was between‭ ‬51‭ ‬and‭ ‬60‭ ‬years old when he died a slow,‭ ‬painful death.

The researchers subjected the mummy to powerful Multi Detector Computerised Tomography‭ (‬MDCT‭) ‬scans.‭ ‬The specially designed protocol produced‭ "really unusual high quality images,‭" ‬Prates reports.

Digital X-rays showed that M1‭ ‬had been buried with crossed arms‭ (‬a common pose in Ptolemaic mummies,‭ ‬although in the New Kingdom it was often associated with royals‭) ‬and suffered from lumbosacral osteoarthritis,‭ ‬which was probably related to a lower lumbar scoliosis.

Several‭ ‬post-mortem fractures,‭ ‬possibly produced by mishandling when the mummy was transported to Europe,‭ ‬afflicted the body.

But that wasn't all they found.‭ ‬A pattern of round and dense tumors,‭ ‬measuring between‭ ‬0.03‭ ‬and‭ ‬0.59‭ ‬inches,‭ ‬interspersed‭ ‬M1‭’‬s pelvis and lumbar spine.‭

"The bone lesions were considered very suggestive of metastatic prostate cancer,‭" ‬wrote the researchers.

Indeed,‭ ‬prostatic carcinoma typically spreads to the pelvic region,‭ ‬the lumbar spine,‭ ‬the upper arm and leg bones,‭ ‬the ribs,‭ ‬ultimately reaching most of the skeleton.‭

Prates and colleagues‭ ‬considered other diseases as alternatives.‭ ‬But‭ ‬M1‭'‬s sex,‭ ‬age,‭ ‬the‭ ‬distribution pattern of the lesions,‭ ‬their shape and density,‭ ‬strongly argued for prostate cancer.

"It is the oldest known case of prostate cancer in ancient Egypt and the‭ ‬second‭ ‬oldest case in history,‭" ‬Prates said.

The earliest diagnosis of‭ ‬metastasising prostate carcinoma came in‭ ‬2007,‭ ‬when researchers investigated the skeleton of a‭ ‬2,700-year-old Scythian king who died,‭ ‬aged‭ ‬40-50,‭ ‬in the steppe of Southern Siberia,‭ ‬Russia.
‭
"This study shows that cancer did exist in antiquity,‭ ‬for sure in ancient Egypt.‭ ‬The main reason for the scarcity of examples found today might be the lower prevalence of carcinogens and the shorter life expectancy,‭" ‬Paula Veiga,‭ ‬a researcher in Egyptology,‭ ‬said.

Moreover,‭ ‬high-resolution CT scanners,‭ ‬able to detect tiny‭ ‬tumors‭ (‬measuring‭ ‬0.03-0.07‭ ‬inches in diameter‭)‬,‭ ‬became available only in‭ ‬2005.‭ ‬This suggests that earlier researchers might have missed several cases.
‭
"This technology improved significantly the interpretation of data.‭ ‬Radiology,‭ ‬and its latest developments,‭ ‬like high resolution CT scan,‭ ‬is a phenomenal non-destructive tool in many fields of art and archeology,‭"‬ Prates said.

Monday, June 6, 2011

Targeted cancer therapy kills prostate tumor cells

A new targeted therapy for prostate cancer halts tumor growth in animals with advanced prostate cancer that is resistant to hormone therapy, a new study finds.

The results will be presented Saturday at The Endocrine Society’s 93rd Annual Meeting in Boston.

“This targeted therapy may provide a treatment breakthrough that will extend the lives of men with advanced, hormone-refractory prostate cancer,” said lead investigator Shuk-mei Ho, PhD, chairwoman of the Department of Environmental Health at the University of Cincinnati.

Men with prostate cancer that has recurred or has spread outside the prostate routinely receive androgen deprivation therapy, which blocks the action of the male hormones.

This castration occurs through surgical removal of both testes or more often with medications. Although effective, this hormone-blocking treatment eventually stops working in some patients, Ho said.

“These patients are left with very few treatment options and usually succumb quickly to the disease,” she said.

Ho’s team previously found they can inhibit the growth of prostate cancer cell lines in culture by targeting and activating a protein called G protein-coupled receptor 30 (GPR30) using the experimental drug G-1, a GPR30 agonist, or stimulator.

In their new study, funded by the Veterans Affairs and the National Institutes of Health, Ho and her co-workers tested G-1 in an animal model of castration-resistant prostate cancer.

They implanted human prostate cancer cells beneath the skin of male mice. The established tumor regressed upon castration and after the cancer relapsed, they injected the mice with a low dose of G-1.

They also gave G-1 to noncastrated, or “intact,” male mice that had prostate tumors. In these intact mice that still had male hormones, G-1 did not stop growth of the prostate tumors or cause substantial death of tumor cells (necrosis), they found.

“Surprisingly, G-1 was highly effective in halting the growth of the tumors that re-emerged after castration,” Ho said.

The castration-resistant tumors showed a 65 percent necrosis. These mice had increased expression of GPR30 after castration, which Ho believes sensitised prostate tumors to the cell growth-inhibiting effects of G-1.

“These results mean G-1 won’t work without androgen deprivation therapy,” she said.

Therefore, Ho reported, the window of time when this targeted therapy might be effective for treating hormone-resistant prostate cancer is after androgen deprivation therapy.

She said she believes G-1 can make androgen blockade more effective. G-1 caused no harm to the prostate or other vital organs in mice, she added.

Although GPR30 may have a role in cell growth in female tissues, Ho said it appears to have the opposite effect in men with hormone-resistant prostate cancer.

“The beauty of this GPR30 is that it does not have any estrogen, and so it will not cause any estrogen related side effects.” she said.

Monday, November 29, 2010

New Research: Prostrate Cancer Tumour Imaging

More than 200,000 men are diagnosed with prostate cancer each year and 28,000 die from it, making it one of the most common cancer in men nationwide and also one of the leading causes of cancer death in men, according to the Centres for Disease Control.

Yet the disease ranges widely in its rate of growth and aggressiveness, according to John Kurhanewicz, PhD, a UCSF expert in prostate cancer imaging. As a result, there is great debate over the ideal strategy for treating the disease, he said, leaving patients with a difficult and potentially life-changing decision over how aggressively to respond to the disease.

“This test could give both physicians and patients the information they need to make that decision,” said Kurhanewicz, whose work with Dan Vigneron, PhD, and their colleagues from the UCSF Department of Radiology and Biomedical Imaging first linked a prostate tumour’s production of lactate to tumour aggressiveness. Other researchers also have linked that lactate production to tumour aggressiveness and response to therapy in other cancers.

The method uses compounds involved in normal tissue function — in this case, pyruvate, which is a naturally occurring by-product of glucose, and lactate, also known as lactic acid — and uses newly developed equipment to increase the visibility of those compounds by a factor of 50,000 in a magnetic resonance imaging (MRI) scanner.

That process requires pyruvate to be prepared in a strong magnetic field at a temperature of minus 272O C, then rapidly warmed to body temperature and transferred to the patient in an MRI scanner before the polarisation decays back to its native state.

The result is a highly defined and clear image of the tumour’s outline, as well as a graph of the amount of pyruvate in the tumour and the rate at which the tumour converts the pyruvate into lactate.

The sterile production process requires a dedicated clinical pharmacist with the knowledge of both quality control and of clinical practice.

The procedure must take place within minutes, which meant integrating a clean room into the scanning facility. QB3 also worked with GE Healthcare in designing Byers Hall, in which the Surbeck Laboratory of Advanced Imaging is housed, to accommodate the extremely strong magnetic field of the MRI scanner and enable time-sensitive experiments.

“All of that insight is why we moved this technology to Northern California,” said Jonathan Murray, general manager, Metabolic Imaging at GE Healthcare. “This is a huge accomplishment UCSF and QB3 have achieved.

They brought together the best engineering from UC Berkeley and the best bioscience and pharmacy knowledge from UCSF, and are now demonstrating the technology in a world-renowned academic medical centre.

We are delighted with the speed of progress of this collaboration. The science is very exciting.”

Wednesday, September 15, 2010

Blood test can accurately predict death from prostate cancer

Researchers at Memorial Sloan-Kettering Cancer Center found that a blood test given to men who are 60 can tell if they will die from prostate cancer up to 25 years in advance.

It’s the leading cause of death for men behind lung cancer. 1 out of every 6 men will be diagnosed with prostate cancer in his lifetime.

“We know that screening detects many prostate cancers that are not harmful, leading to anxiety and unnecessary treatment. It is our ability to determine the risk of the really aggressive cancers that makes this approach of such great potential value,” Sloan-Kettering’s researcher Andrew Vickers said in a statement.

After studying blood samples from a thousand men born in 1921 — part of the Malmo Preventive Project in early 1980s— scientists found that the men who had high levels of PSA were the ones who were likely to die from prostate cancer. Indeed, the majority of the men who were diagnosed with prostate cancer had the top 25 percent PSA levels. And those who had PSA levels below 1 ng / ml, basically had no chance of dying from prostate cancer.

The researchers found that half the men fell into this low level PSA range. Distinquishing which cancers are more aggressive could help researchers treat individual cases accordingly.

However, there’s evidence that PSA tests don’t reduce deaths — and perhaps we should starting screening later at age 60 instead of 40.

According to WebMD:

“When we do routine mass screening for prostate cancer there are winners and losers,” Andriole said to WebMD. “Some men clearly benefit from early detection and early treatment. But other men are losers. They are diagnosed with a cancer, undergo unnecessary treatment and have side effects, and they go through all pain and anxiety associated with having cancer.”

In other news, researchers found that biomarkers can diagnose Alzheimer’s disease long before it manifests. And as I mentioned this week, biomarkers associated with cancer were found in swimmers who soaked themselves in chlorine-drenched pools.